Live at IDWeek 2014

Ceftaroline Shows Similar Cure Rates for SSTIs in Obese, Non-Obese Patients

A recent study comparing the efficacy and safety of ceftaroline vs. vancomycin in obese (BMI ≥30) and non-obese (BMI <30) patients found that ceftaroline therapy was associated with similar clinical cure rates in both non-obese as well as among obese patients, when compared with vancomycin (with or without gram-negative coverage combination therapy) in patients with skin and soft tissue infections (SSTI).

QUAD Regimen Demonstrates High SVR12 Rates in Patients with HCV Genotype 1/4 Infection

The QUAD regimen—daclatasvir and asunaprevir plus peginterferon alfa-2a and ribavirin (DCV+ASV+pegIFN/RBV)—demonstrated high sustained virologic response rates of 93% at post-treatment Week 12 (SVR12) in genotype 1 (GT 1) and 100% in genotype 4 (GT 4) patients with hepatitis C virus who were prior null or partial responders to pegIFN/RBV.